Literature DB >> 18074125

Evaluation of cystine transport in cultured human kidney cells and establishment of cystinuria type I phenotype by antisense technology.

Gunnar Wendt-Nordahl1, Sreedhar Sagi, Christian Bolenz, Peter Alken, Maurice Stephan Michel, Thomas Knoll.   

Abstract

Cystinuria is a rare hereditary disease resulting in recurrent stone formation and the need for repeated invasive interventions. So far, two responsible genes have been identified which encode the two transporters, rBAT and b(0,+)AT forming a heterodimer to transport cystine in proximal tubular cells (PTC) and whose defect results in increased excretion of cystine. A human cell line mimicing the phenotype of cystinuria in vitro is yet to be developed. Human kidney (HK)-2 is a PTC line derived from normal HK. After determining the presence of rBAT gene by RT-PCR and Western blot analysis, radioactively labeled cystine (S(35)) was used to evaluate the functional presence of the amino acid transport in HK-2 cells when cultured in vitro. To achieve a cystinuria type I phenotype in HK-2 cells, the rBAT gene was silenced using antisense oligonucleotides complimentary to human rBAT mRNA. The reduced transport activity of cystine was then determined by radiolabeled cystine uptake measurements. RT-PCR and Western blot confirmed the expression of the rBAT gene in HK-2 cells. Considerable transport of the radio labeled cystine was observed in HK-2 cells and was linearly dependent on the incubation time with the amino acid. The cystine transport in rBAT knockdown cells after incubation with antisense oligonucleotides was significantly lower compared to control (0.76 vs. 0.98%; P=0.0008), proving a transient knock-down of the rBAT gene. This study demonstrates the presence of the b(0,+) amino acid transport system in human proximal tubular HK-2 cells when cultured in vitro. Inhibition of this transport system is possible by using antisense technology. A permanent inhibition of the cystine transport, based on our model, would be useful for the development and evaluation gene therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18074125     DOI: 10.1007/s00240-007-0127-z

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  17 in total

1.  Luminal heterodimeric amino acid transporter defective in cystinuria.

Authors:  R Pfeiffer; J Loffing; G Rossier; C Bauch; C Meier; T Eggermann; D Loffing-Cueni; L C Kühn; F Verrey
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

Review 2.  The genetics of heteromeric amino acid transporters.

Authors:  Manuel Palacín; Virginia Nunes; Mariona Font-Llitjós; Maite Jiménez-Vidal; Joana Fort; Emma Gasol; Marta Pineda; Lidia Feliubadaló; Josep Chillarón; Antonio Zorzano
Journal:  Physiology (Bethesda)       Date:  2005-04

Review 3.  Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up.

Authors:  Thomas Knoll; Antonia Zöllner; Gunnar Wendt-Nordahl; Maurice Stephan Michel; Peter Alken
Journal:  Pediatr Nephrol       Date:  2004-11-25       Impact factor: 3.714

4.  Expression cloning of a human renal cDNA that induces high affinity transport of L-cystine shared with dibasic amino acids in Xenopus oocytes.

Authors:  J Bertran; A Werner; J Chillarón; V Nunes; J Biber; X Testar; A Zorzano; X Estivill; H Murer; M Palacín
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

5.  Poly(A)+ RNA from rabbit intestinal mucosa induces b0,+ and y+ amino acid transport activities in Xenopus laevis oocytes.

Authors:  S Magagnin; J Bertran; A Werner; D Markovich; J Biber; M Palacín; H Murer
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

6.  Cystine transport activity of heterozygous rBAT mutants expressed in Xenopus oocytes.

Authors:  Masanari Ishihara; Takehiko Ogura; Koichiro Akakura; Ken-ichi Egoshi; Kazuo Mikami; Haruaki Nakaya; Haruo Ito
Journal:  Nephron       Date:  2002-06       Impact factor: 2.847

7.  The population-specific distribution and frequencies of genomic variants in the SLC3A1 and SLC7A9 genes and their application in molecular genetic testing of cystinuria.

Authors:  Christa Schmidt; Udo Vester; Albrecht Hesse; Sven Lahme; Florian Lang; Klaus Zerres; Thomas Eggermann
Journal:  Urol Res       Date:  2004-02-26

8.  Molecular genetics of cystinuria: mutation analysis of SLC3A1 and evidence for another gene in type I (silent) phenotype.

Authors:  I Saadi; X Z Chen; M Hediger; P Ong; P Pereira; P Goodyer; R Rozen
Journal:  Kidney Int       Date:  1998-07       Impact factor: 10.612

9.  The rBAT gene is responsible for L-cystine uptake via the b0,(+)-like amino acid transport system in a "renal proximal tubular" cell line (OK cells).

Authors:  C Mora; J Chillarón; M J Calonge; J Forgo; X Testar; V Nunes; H Murer; A Zorzano; M Palacín
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

10.  Apical heterodimeric cystine and cationic amino acid transporter expressed in MDCK cells.

Authors:  Christian Bauch; François Verrey
Journal:  Am J Physiol Renal Physiol       Date:  2002-07
View more
  4 in total

Review 1.  Cystinuria: mechanisms and management.

Authors:  Donna J Claes; Elizabeth Jackson
Journal:  Pediatr Nephrol       Date:  2012-01-27       Impact factor: 3.714

Review 2.  Kidney stones: an update on current pharmacological management and future directions.

Authors:  Hongshi Xu; Anna L Zisman; Fredric L Coe; Elaine M Worcester
Journal:  Expert Opin Pharmacother       Date:  2013-03       Impact factor: 3.889

3.  Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies.

Authors:  Maria Goretti Moreira Guimarães Penido; Marcelo de Sousa Tavares
Journal:  World J Nephrol       Date:  2015-09-06

Review 4.  How should patients with cystine stone disease be evaluated and treated in the twenty-first century?

Authors:  Kim Hovgaard Andreassen; Katja Venborg Pedersen; Susanne Sloth Osther; Helene Ulrik Jung; Søren Kissow Lildal; Palle Joern Sloth Osther
Journal:  Urolithiasis       Date:  2015-11-27       Impact factor: 3.436

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.